Investigation of Drug-Interaction Potential for Arthritis Dietary Supplements: Chondroitin Sulfate, Glucosamine, and Methylsulfonylmethane
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Su Min | - |
dc.contributor.author | Jo, So Young | - |
dc.contributor.author | Park, Ho-Young | - |
dc.contributor.author | Lee, Yu Ra | - |
dc.contributor.author | Yu, Jun Sang | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2024-01-11T05:00:19Z | - |
dc.date.available | 2024-01-11T05:00:19Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 1420-3049 | - |
dc.identifier.issn | 1420-3049 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/117184 | - |
dc.description.abstract | Osteoarthritis is one of the leading conditions that promote the consumption of these dietary supplements. Chondroitin sulfate, glucosamine, and methylsulfonylmethane are among the prominent alternative treatments for osteoarthritis. In this study, these dietary supplements were incubated with cytochrome P450 isozyme-specific substrates in human liver microsomes, and the formation of marker metabolites was measured to investigate their inhibitory potential on cytochrome P450 enzyme activities. The results revealed no significant inhibitory effects on seven CYPs, consistent with established related research data. Therefore, these substances are anticipated to have a low potential for cytochrome P450-mediated drug interactions with osteoarthritis medications that are likely to be co-administered. However, given the previous reports of interaction cases involving glucosamine, caution is advised regarding dietary supplement–drug interactions. © 2023 by the authors. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Investigation of Drug-Interaction Potential for Arthritis Dietary Supplements: Chondroitin Sulfate, Glucosamine, and Methylsulfonylmethane | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/molecules28248068 | - |
dc.identifier.scopusid | 2-s2.0-85180709629 | - |
dc.identifier.wosid | 001136113100001 | - |
dc.identifier.bibliographicCitation | Molecules, v.28, no.24, pp 1 - 10 | - |
dc.citation.title | Molecules | - |
dc.citation.volume | 28 | - |
dc.citation.number | 24 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 10 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | ACETAMINOPHEN METABOLISM | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | MELOXICAM | - |
dc.subject.keywordPlus | BIOAVAILABILITY | - |
dc.subject.keywordPlus | ITRACONAZOLE | - |
dc.subject.keywordPlus | VORICONAZOLE | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | DECREASES | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.subject.keywordPlus | CODEINE | - |
dc.subject.keywordAuthor | chondroitin sulfate | - |
dc.subject.keywordAuthor | cytochrome P450 | - |
dc.subject.keywordAuthor | glucosamine | - |
dc.subject.keywordAuthor | methylsulfonylmethane | - |
dc.subject.keywordAuthor | osteoarthritis | - |
dc.identifier.url | https://www.mdpi.com/1420-3049/28/24/8068 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.